A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Down 2.0% in August: Crecon
October 10, 2018
- Celgene’s CAR-T Therapy Earns Orphan Status in Japan
October 10, 2018
- Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel
October 10, 2018
- 3 Japan Major Pharmas to Launch 2nd Open Drug Reposition Program
October 10, 2018
- Funding Disclosures Reveal Changes in Money Flows; Biz Models, Pricing Reform Driving the Shift
October 9, 2018
- Osaka Univ. Spinout FunPep Raises 460 Million Yen
October 9, 2018
- Canada Approves Mitsubishi Tanabe’s ALS Med Radicava
October 9, 2018
- Belviq Reduces Risk of Progression to Type 2 Diabetes: Eisai
October 9, 2018
- Takeda Alumni Shareholders Send Open Letter Questioning Shire Buyout
October 9, 2018
- Reldesemtiv Shows Efficacy for Spinal Muscular Atrophy in PII: Astellas/Cytokinetics
October 9, 2018
- I/O in Lung Cancer - 7: Oncologist Sees Promise in I/O-I/O Combos, Prods Quest for Cure
October 5, 2018
- Fujifilm Develops New Technology to Search and Design Candidate Compounds Using Structural Formulas Alone
October 5, 2018
- Novo’s Oral GLP-1 Analogue Semaglutide Comparable to Subcutaneous Dulaglutide in No. of AEs: Japan PIIIa Study
October 5, 2018
- Blincyto OK Now in Hand, Amgen Astellas JV Revs Up for Foray into Japan Oncology Market
October 4, 2018
- Amgen to Remain Active Investor in Japan as It Eyes 2020 Launch of Stand-Alone Subsidiary
October 4, 2018
- Daiichi Sankyo/Kite’s CAR-T Cell Therapy Scoops Up Orphan Status for B-Cell Lymphoma
October 4, 2018
- Bavencio on Back Foot, but Merck KGaA Has High Hopes for Next-Gen I/O Therapy M7824
October 3, 2018
- Fujifilm, Taisho Detail Sales Schemes after Tie-Up Dissolution Next March
October 3, 2018
- Kaken Grants Distribution Rights for Efinaconazole to Main Life in Hong Kong, Macau
October 3, 2018
- Adcetris Improves PFS as Frontline Therapy for PTCL in PIII: Takeda/Seattle Genetics
October 3, 2018
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…